This topic contains a solution. Click here to go to the answer

Author Question: Argenbright, Wachenhut and Huntleigh Security companies are currently banned from engaging in ... (Read 30 times)

burchfield96

  • Hero Member
  • *****
  • Posts: 610
Argenbright, Wachenhut and Huntleigh Security companies are currently banned from engaging
  in screening activities in the United States.
 
  Indicate whether the statement is true or false

Question 2

Which of the following was recommended by the President's Working Group on Unlawful Conduct on the Internet?
 
  a. Allow ISPs to discard records after 24 hours.
  b. Restrict the training of average users, to prevent them from engaging in unlawful activity.
  c. Make exclusive use of traditional statutes rather than passing amendments or new legislation.
  d. Encourage local agencies to establish a presence on the Net.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

brittiany.barnes

  • Sr. Member
  • ****
  • Posts: 321
Answer to Question 1

TRUE

Answer to Question 2

d



burchfield96

  • Hero Member
  • *****
  • Posts: 610
Both answers were spot on, thank you once again




 

Did you know?

Disorders that may affect pharmacodynamics include genetic mutations, malnutrition, thyrotoxicosis, myasthenia gravis, Parkinson's disease, and certain forms of insulin-resistant diabetes mellitus.

Did you know?

As of mid-2016, 18.2 million people were receiving advanced retroviral therapy (ART) worldwide. This represents between 43–50% of the 34–39.8 million people living with HIV.

Did you know?

In the United States, congenital cytomegalovirus causes one child to become disabled almost every hour. CMV is the leading preventable viral cause of development disability in newborns. These disabilities include hearing or vision loss, and cerebral palsy.

Did you know?

A seasonal flu vaccine is the best way to reduce the chances you will get seasonal influenza and spread it to others.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library